Impact of subclinical hypothyroidism on health-related quality of life: a narrative review

A biochemical diagnosis of subclinical hypothyroidism (SCH) is defined by an elevated serum thyroid-stimulating hormone (TSH) with a normal serum free thyroxine (FT4). This paper discusses SCH in the Australian population, the impact of SCH on health-related quality of life (HRQoL), and the evidence for thyroid hormone therapy as well as exercise therapy to improve HRQoL in SCH. The prevalence of SCH in Australia is approximately 4-5% and is higher in females and the elderly. Current evidence suggests thyroid hormone therapy is not associated with an improvement in HRQoL. However, there does appear to be a subgroup of those with SCH that experience an impairment in HRQoL who may potentially benefit from treatment. Because the majority of research to date has been done in elderly, largely asymptomatic individuals, this may not be representative of the entire SCH population. In addition, alternative treatments, such as exercise therapy, have not been well explored in the literature, despite exercise therapy's effects on HRQoL in other populations. Further research is required to define clearly which individuals with SCH are likely to experience an impaired HRQoL, as well as explore the effects of thyroid hormone therapy and exercise therapy in these individuals.

Automated summary

Subclinical hypothyroidism (SCH) is common in the Australian population, with higher prevalence in females and the elderly. Current evidence suggests that thyroid hormone therapy may not improve health-related quality of life (HRQoL) in SCH patients, but there may be a subgroup that could benefit. Further research is needed to identify individuals with SCH who may have impaired HRQoL and to explore the effects of thyroid hormone therapy and exercise therapy in these individuals.